Vir Biotechnology, Inc. (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 69,839 Shares

Vir Biotechnology, Inc. (NASDAQ:VIRGet Rating) major shareholder Endurance (Cayman) Ltd Svf sold 69,839 shares of the company’s stock in a transaction on Thursday, January 19th. The shares were sold at an average price of $26.56, for a total transaction of $1,854,923.84. Following the completion of the sale, the insider now directly owns 19,527,382 shares in the company, valued at $518,647,265.92. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

  • On Tuesday, January 17th, Endurance (Cayman) Ltd Svf sold 88,372 shares of Vir Biotechnology stock. The shares were sold at an average price of $26.24, for a total transaction of $2,318,881.28.
  • On Friday, January 13th, Endurance (Cayman) Ltd Svf sold 94,199 shares of Vir Biotechnology stock. The shares were sold at an average price of $26.54, for a total transaction of $2,500,041.46.
  • On Wednesday, January 11th, Endurance (Cayman) Ltd Svf sold 79,065 shares of Vir Biotechnology stock. The shares were sold at an average price of $26.24, for a total transaction of $2,074,665.60.
  • On Monday, January 9th, Endurance (Cayman) Ltd Svf sold 34,801 shares of Vir Biotechnology stock. The shares were sold at an average price of $25.85, for a total transaction of $899,605.85.
  • On Friday, January 6th, Endurance (Cayman) Ltd Svf sold 66,179 shares of Vir Biotechnology stock. The shares were sold at an average price of $26.13, for a total transaction of $1,729,257.27.
  • On Tuesday, January 3rd, Endurance (Cayman) Ltd Svf sold 8,177 shares of Vir Biotechnology stock. The shares were sold at an average price of $25.58, for a total transaction of $209,167.66.
  • On Tuesday, December 27th, Endurance (Cayman) Ltd Svf sold 6,850 shares of Vir Biotechnology stock. The stock was sold at an average price of $25.59, for a total transaction of $175,291.50.
  • On Thursday, December 22nd, Endurance (Cayman) Ltd Svf sold 95,144 shares of Vir Biotechnology stock. The stock was sold at an average price of $26.07, for a total transaction of $2,480,404.08.
  • On Tuesday, December 20th, Endurance (Cayman) Ltd Svf sold 104,026 shares of Vir Biotechnology stock. The stock was sold at an average price of $25.53, for a total transaction of $2,655,783.78.
  • On Monday, December 5th, Endurance (Cayman) Ltd Svf sold 8,831 shares of Vir Biotechnology stock. The stock was sold at an average price of $27.25, for a total transaction of $240,644.75.

Vir Biotechnology Price Performance

Shares of VIR stock opened at $29.16 on Tuesday. The firm has a 50-day moving average of $26.29 and a 200-day moving average of $25.06. The company has a market cap of $3.88 billion, a P/E ratio of 3.43 and a beta of 0.15. Vir Biotechnology, Inc. has a one year low of $18.05 and a one year high of $35.48.

Vir Biotechnology (NASDAQ:VIRGet Rating) last announced its earnings results on Thursday, November 3rd. The company reported $1.30 EPS for the quarter, beating the consensus estimate of $0.01 by $1.29. The firm had revenue of $374.56 million during the quarter, compared to analysts’ expectations of $153.79 million. As a group, research analysts expect that Vir Biotechnology, Inc. will post 4.61 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

VIR has been the topic of several research reports. SVB Leerink upped their price objective on shares of Vir Biotechnology from $40.00 to $45.00 and gave the stock an “outperform” rating in a report on Friday, November 4th. Morgan Stanley upped their price objective on shares of Vir Biotechnology from $15.00 to $18.00 and gave the stock an “underweight” rating in a report on Friday, November 4th. Needham & Company LLC lowered their price objective on shares of Vir Biotechnology from $35.00 to $32.00 and set a “buy” rating on the stock in a report on Friday, November 4th. Finally, TheStreet upgraded shares of Vir Biotechnology from a “d” rating to a “c-” rating in a report on Monday, October 10th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $52.50.

Hedge Funds Weigh In On Vir Biotechnology

Several institutional investors have recently added to or reduced their stakes in the stock. SummerHaven Investment Management LLC grew its position in Vir Biotechnology by 1.7% during the fourth quarter. SummerHaven Investment Management LLC now owns 25,343 shares of the company’s stock valued at $641,000 after buying an additional 416 shares during the period. State of Alaska Department of Revenue boosted its position in Vir Biotechnology by 0.9% during the fourth quarter. State of Alaska Department of Revenue now owns 52,834 shares of the company’s stock worth $1,337,000 after purchasing an additional 491 shares during the period. Royal Bank of Canada boosted its position in Vir Biotechnology by 14.1% during the third quarter. Royal Bank of Canada now owns 4,125 shares of the company’s stock worth $79,000 after purchasing an additional 510 shares during the period. Commonwealth Equity Services LLC boosted its position in Vir Biotechnology by 0.6% during the third quarter. Commonwealth Equity Services LLC now owns 85,298 shares of the company’s stock worth $1,644,000 after purchasing an additional 523 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its position in Vir Biotechnology by 0.5% during the second quarter. Massachusetts Financial Services Co. MA now owns 105,665 shares of the company’s stock worth $2,691,000 after purchasing an additional 537 shares during the period. Institutional investors own 74.97% of the company’s stock.

About Vir Biotechnology

(Get Rating)

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.

See Also

Insider Buying and Selling by Quarter for Vir Biotechnology (NASDAQ:VIR)

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.